Menarini Group announces Positive Topline Data from Pivotal Phase 3 BROADWAY & TANDEM Clinical Trials Evaluating Obicetrapib and the Fixed-Dose Combination Obicetrapib with Ezetimibe 10 mg

Menarini Industrie Farmaceutiche Riunite United Kingdom United States of America France Germany Spain Italy California New Jersey

View original content:https://www.prnewswire.co.uk/news-releases/menarini-group-announces-positive-topline-data-from-pivotal-phase-3-broadway--tandem-clinical-trials-evaluating-obicetrapib-and-the-fixed-dose-combination-obicetrapib-with-ezetimibe-10-mg-302332562.html